NCT02953054已完成2 期
A Double-Blind, Placebo-Controlled, Single-Dose Evaluation of the Dexmedetomidine Transdermal System for Post-Operative Analgesia Following Bunionectomy
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 88
- 试验地点
- 2
- 主要终点
- Time-interval weighted summed pain intensity (SPI), measured using the 11 point (0 to 10) numeric rating scale (NRS) at designated time points from 4 to 24 hours following surgery (NRSSPI).
研究概览
简要总结
The purpose of this study is to evaluate whether the DMTS, compared with a placebo patch, will provide adequate pain relief during the first 3 days following bunionectomy surgery.
详细描述
The primary objective of this study is to evaluate the analgesic efficacy of the DMTS, compared with placebo in subjects with acute moderate to severe pain following unilateral bunionectomy.
The secondary objectives are:
- To assess the safety and tolerability of the DMTS, including assessment of skin irritation
- To assess adhesion of the DMTS
- To assess the sedation effect of the DMTS
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Voluntarily provide written informed consent.
- •Male or female, ≥ 18 years of age.
- •Scheduled to undergo a primary unilateral first metatarsal bunionectomy repair.
- •Have a physical status classification of 1 or 2 per the American Society of Anesthesiology.
- •Non-smoker for at least 1 year prior to screening; non-smoking is defined by cessation of smoking and use of all other tobacco and nicotine products (including chewing tobacco, snuff, e-cigarettes, nicotine patches, etc.).
- •Female subjects are eligible only if all the following apply:
- •Not pregnant, not lactating, and not planning to become pregnant during the study
- •Surgically sterile; or at least 2 years postmenopausal; or have a monogamous partner who is surgically sterile; or have a same gender sex partner; or is practicing double-barrier contraception; or practicing abstinence; or using an insertable, injectable, transdermal, or combination oral contraceptive
- •Male subjects with female sex partners must be surgically sterile or commit to the use of a reliable method of birth control.
- •Have a body weight > 50 kg, and body mass index of 22 to 38 kg/m2, inclusive.
- •Able to understand the study procedures, comply with all study procedures, and agree to participate in the study program for its full duration.
排除标准
- •Have a known sensitivity to dexmedetomidine or any excipient in the DMTS/placebo or to any peri- or postoperative medication whose use is required in this study.
- •Have a skin abnormality (eg, scar, tattoo) or unhealthy skin condition (eg, burns, wounds) at the patch application site, according to examination by the investigator at screening or admission to the clinic prior to surgery.
- •Have a clinically significant abnormal clinical laboratory test value.
- •Have history of or positive test results for the human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.
- •Have a history or clinical manifestations of: a significant renal, hepatic, cardiovascular, metabolic, neurologic, or psychiatric condition; congestive heart failure, peptic ulcer, gastrointestinal bleeding, or other condition that would preclude participation in the study.
- •Have a history of migraine or frequent headaches, seizures, or are currently taking anticonvulsants.
- •Have another painful physical condition that may confound the assessments of postoperative pain.
- •Have a history of syncope or other syncopal attacks.
- •Have evidence of a clinically significant 12-lead ECG abnormality.
- •Have a history of alcohol abuse or prescription/illicit drug abuse.
- •Have positive results on the urine drug screen or alcohol breath test indicative of illicit drug or alcohol use at screening and/or clinic check-in.
- •Have a history or evidence of clinically significant orthostatic hypotension.
- •Have a resting heart rate of < 50 beats per minute or systolic blood pressure < 100 mmHg.
- •Have been receiving or have received opioid therapy chronically for > 2 weeks within the month prior to dosing of the study drug.
- •Use concurrent therapy that could interfere with the evaluation of efficacy or safety, such as any drugs which in the investigator's opinion may exert significant analgesic properties or act synergistically with dexmedetomidine.
- •Have had an upper respiratory tract infection within 14 days prior to dosing of the study drug.
- •Have utilized oral or injectable corticosteroids within 14 days prior to dosing of the study drug (intranasal and topical corticosteroid use during this time period is allowed).
- •Have received any investigational product within 30 days prior to dosing of the study drug.
- •Have previously received DMTS in a clinical trial.
- •Sensitivity to opioids, nonsteroidal anti-inflammatory drugs, or antibiotics.
- •In the opinion of the investigator or designee, is considered unsuitable for study entry and/or is unlikely to comply with the study protocol for any reason.
研究组 & 干预措施
DMTS
Active Comparator
DMTS applied to the upper arm
干预措施: DMTS (Drug)
Placebo
Placebo Comparator
Placebo patches to match DMTS applied to the upper arm
干预措施: Placebo (Drug)
结局指标
主要结局
Time-interval weighted summed pain intensity (SPI), measured using the 11 point (0 to 10) numeric rating scale (NRS) at designated time points from 4 to 24 hours following surgery (NRSSPI).
时间窗: From 4 to 24 hours following surgery
次要结局
- The time to first use of rescue pain medication(intraoperative)
- Time-interval weighted summed pain intensity over various time intervals(Up to 72 hours after surgery)
- The proportion of subjects using opioid rescue pain medication(Up to 72 hours after surgery)
研究者
研究点 (2)
Loading locations...
相似试验
招募中
2 期
Dexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer's TypeAgitationNCT06052254Teikoku Pharma USA, Inc.150
终止
2 期
Evaluation of the Dexmedetomidine Transdermal Systems for Postoperative Analgesia Following AbdominoplastyPain, PostoperativeNCT05412992Teikoku Pharma USA, Inc.179
已完成
3 期
Evaluation of Deep Transcranial Magnetic Stimulation (DTMS) With the H-ADD Coil as an Aid to Smoking Cessation.Smoking CessationNCT02126124Brainsway224
已完成
3 期
IDEA-033 Three Months Dose Finding in OA Followed by IDEA-033 Three Months Extension in OAKnee OsteoarthritisNCT00316784IDEA AG704
已完成
3 期
Evaluate the Efficacy &Safety of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHDADHDNCT00499863Noven Therapeutics217